Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody

Wu, Zherui; Fournel, Ludovic; Städler, Nicolas; Liu, Jin; Boullier, Agnès; Hoyeau, Nadia; Fléjou, Jean François; Duchatelle, V.; Djebrani‐Oussedik, Nouzha; Agopiantz, Mikaël; Ségal-Bendirdjian, Évelyne; Gompel, Anne; Alifano, Marco; Melander, Olle; Trédaniel, Jean; Forgez, Patricia

doi:10.1016/j.canlet.2018.12.007

Cited by 17 publications

(30 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same research group showed that high expression of NTSR1 was an independent negative prognostic marker in 389 patients with lung adenocarcinoma, stages I to III [12]. NTSR1 overexpression has also been correlated to worse sensitivity to platinum-based chemotherapy in patients with NSCLC [18]. Currently, standard chemotherapy agents include platinum-salt compound with an antimetabolite or a spindle poison [18].…”

Section: Lung Cancermentioning

confidence: 99%

“…NTSR1 overexpression has also been correlated to worse sensitivity to platinum-based chemotherapy in patients with NSCLC [18]. Currently, standard chemotherapy agents include platinum-salt compound with an antimetabolite or a spindle poison [18]. Although this regime increases overall survival (OS) up to 12 months or more, patients still develop progressive disease and die [18].…”

Section: Lung Cancermentioning

confidence: 99%

“…Currently, standard chemotherapy agents include platinum-salt compound with an antimetabolite or a spindle poison [18]. Although this regime increases overall survival (OS) up to 12 months or more, patients still develop progressive disease and die [18]. Targeted therapies are now recommended in 15 to 20% of NSCLC patients who have specific mutations (e.g.…”

Section: Lung Cancermentioning

confidence: 99%

See 2 more Smart Citations

The role of Neurotensin and its receptors in non-gastrointestinal cancers: a review

et al. 2020

View full text Add to dashboard Cite

Background: Neurotensin, originally isolated in 1973 has both endocrine and neuromodulator activity and acts through its three main receptors. Their role in promoting tumour cell proliferation, migration, DNA synthesis has been studied in a wide range of cancers. Expression of Neurotensin and its receptors has also been correlated to prognosis and prediction to treatment. Main body: The effects of NT are mediated through mitogen-activated protein kinases, epidermal growth factor receptors and phosphatidylinositol-3 kinases amongst others. This review is a comprehensive summary of the molecular pathways by which Neurotensin and its receptors act in cancer cells. Conclusion: Identifying the role of Neurotensin in the underlying molecular mechanisms in various cancers can give way to developing new agnostic drugs and personalizing treatment according to the genomic structure of various cancers.

show abstract

Section: Lung Cancermentioning

confidence: 99%

Section: Lung Cancermentioning

confidence: 99%

Section: Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

The role of Neurotensin and its receptors in non-gastrointestinal cancers: a review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Non‐small cell lung cancer (NSCLC) is one of the leading causes of cancer‐related death worldwide . Despite recent therapeutic advances, platinum‐based chemotherapy is still a widely used adjuvant therapeutic strategy for patients with advanced NSCLC . Cisplatin is one of the most commonly used chemotherapy drugs, but its use is limited because of acquired drug resistance.…”

Section: Introductionmentioning

confidence: 99%

“…1 Despite recent therapeutic advances, platinum-based chemotherapy is still a widely used adjuvant therapeutic strategy for patients with advanced NSCLC. 2 Cisplatin is one of the most commonly used chemotherapy drugs, but its use is limited because of acquired drug resistance. Multiple cellular self-defense adaptations, such as reduced uptake and increased drug efflux, protein inactivation, and increased damage repair, are responsible for cisplatin resistance.…”

Section: Introductionmentioning

confidence: 99%

Knockdown of KLF5 promotes cisplatin‐induced cell apoptosis via regulating DNA damage checkpoint proteins in non‐small cell lung cancer

et al. 2019

View full text Add to dashboard Cite

Background Previous research has revealed that Krüppel‐like factor 5 ( KLF5 ) may affect DNA damage repair pathways; however, the associated molecular mechanisms are unclear. Methods The expression of KLF5 was studied by immunohistochemical staining in paired tumour and normal tissues from 90 patients with ESCC. We studied the effects of KLF5 knockdown on cell proliferation and apoptosis with or without cisplatin treatment in A549 and H1299 cell lines. Moreover, we examined the effect of KLF5 on the DNA damage response. Results KLF5 was significantly overexpressed in non‐small cell lung cancer (NSCLC) tissues, and high KLF5 expression predicted poor prognosis for NSCLC patients. The inhibition of KLF5 markedly augmented cisplatin‐induced cell apoptosis. In addition, we observed that KLF5 knockdown could decrease DNA repair potential by inhibiting H2AX S139 phosphorylation in response to cisplatin. Moreover, silencing of KLF5 in NSCLC cell lines inhibited the phosphorylation of checkpoint kinases Chk1 S345 and Chk2 T68. KLF5 knockdown permits cells with broken or damaged DNA strands to enter mitosis by inhibiting the activation of H2AX, Chk1 and Chk2, resulting in mitotic catastrophe. Conclusion KLF5 plays a significant role in the DNA damage response by regulating DNA damage checkpoint proteins. Inhibition of KLF5 may be a potential therapeutic target for NSCLC patients with cisplatin resistance.

show abstract

SOX9 promotes stemness in the CAL27 cell line of tongue squamous cell carcinoma

Sheng,

Fu,

Zhou

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Tongue squamous cell carcinoma (TSCC) is a prevalent form of oral malignancy, with increasing incidence. Unfortunately, the 5‐year survival rate for patients has not exceeded 50%. Studies have shown that sex‐determining region Y box 9 (SOX9) correlates with malignancy and tumor stemness in a variety of tumors. To investigate the role of SOX9 in TSCC stemness, we analyzed its influence on various aspects of tumor biology, including cell proliferation, migration, invasion, sphere and clone formation, and drug resistance in TSCC. Our data suggest a close association between SOX9 expression and both the stemness phenotype and drug resistance in TSCC. Immunohistochemical experiments revealed a progressive increase of SOX9 expression in normal oral mucosa, paracancerous tissues, and tongue squamous carcinoma tissues. Furthermore, the expression of SOX9 was closely linked to the TNM stage, but not to lymph node metastasis or tumor diameter. SOX9 is a crucial gene in TSCC responsible for promoting the stemness function of cancer stem cells. Developing drugs that target SOX9 is extremely important in clinical settings.

show abstract

Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody

Cited by 17 publications

References 47 publications

The role of Neurotensin and its receptors in non-gastrointestinal cancers: a review

The role of Neurotensin and its receptors in non-gastrointestinal cancers: a review

Knockdown of KLF5 promotes cisplatin‐induced cell apoptosis via regulating DNA damage checkpoint proteins in non‐small cell lung cancer

SOX9 promotes stemness in the CAL27 cell line of tongue squamous cell carcinoma

Contact Info

Product

Resources

About